GT1a中HCV的99.7％SVR固化率

StephenW

HCV 99.7% SVR-Cure Rates in GT1a

from Jules: essentially in treatment-naive GT1 we have 99.7% SVR-cure rates with 1 relapse or viral failure in each of the Mavyret or Epclusa studies of hundreds of patients with either 8 or 12 weeks therapy. Mavyret approved for 8 weeks in GT1 treatment-naives. Vosevi (SOF/Velapasvir/Voxilaprevir) is the approved regimen for previously DAA treated failures. As stated in FDA PI - Mavyret is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both - study results below. Visevi FDA PI says - is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have (1, 2.2, 14): • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. SOF+G/P has been studied, reported results below & effective. Treating former or current IV drug users is no longer contraindicated, as stated by AASLD/IDSA guidelines and it is commonly said now by leading HCV treaters that IVDUs can & should be treated, of course support is needed for these patients regarding adherence & reinfection, reported studies below show good SVR-cure rates for these patients: Simplify, Prevail, C-Edge Co-Star studies.HCV/HIV coinfected respond equally well to HCV therapy. Studies for reatment for HCV patients with kidney disease show excellent results, studies reported below.

GT1a中HCV的99.7％SVR固化率

来自Jules：基本上在初治GT1治疗中，我们有数百例患者接受8周或12周治疗的Mavyret或Epclusa研究中每次治愈率为99.7％，1次复发或病毒衰竭。 Mavyret在GT1治疗天真中批准了8周。 Vosevi（SOF / Velapasvir / Voxilaprevir）是之前DAA治疗失败的批准方案。正如FDA所述，PI-Mavyret也被用于治疗HCV基因1型感染的成人患者，他们以前曾接受过含有HCV NS5A抑制剂或NS3 / 4A蛋白酶抑制剂的治疗方案，但两者都不是两种 - 研究结果如下。 Visevi FDA PI表示 - 用于治疗患有慢性HCV感染但无肝硬化或代偿性肝硬化（Child-Pugh A）的成人患者（1,2,214）：•基因型1,2,3,4,5或6感染，并且先前已用含有NS5A抑制剂的HCV方案治疗。 •基因型1a或3感染，以前曾用含有sofosbuvir但不含NS5A抑制剂的HCV方案进行治疗。已经研究过SOF + G / P，报告结果如下＆有效。正如AASLD / IDSA指南所指出的那样，治疗过去或现在的静脉注射吸毒者不再是禁忌症，现在通常由主要的HCV治疗者说IVDUs可以和应该得到治疗，当然这些患者需要支持依从性和再感染，以下报道的研究显示这些患者有良好的SVR治愈率：简化，普及，C-Edge Co-Star研究.HCV / HIV合并感染对HCV治疗反应同样良好。对于患有肾病的HCV患者的治疗研究显示出优异的结果，下面报道了研究。